Top Ten for the week of 10/19/09
This week was kinda slow. None of the moves were very exciting. Michael Wolfe going back to Benchmark as an EIR was interesting, but not earth shattering. He obviously has a track record of building successful companies (his last, Vontu, was acquired by Symantec for $350m). There were some interesting Executive Page removals, but I don't cover those in the blog (I don't want to speculate why someone was removed).
Most interesting to me was the work that I did over the weekend for some upcoming feature additions to our TechnamesDB database. We have been tracking org structures in our database for 20+ years. I have nearly finished what will be probably the coolest feature to date, clickable, graphical org charts. This feature should be available in TechnamesDB by the end of the week. As soon as it is completed, I will be adding a video to our support page to show how it works.
Top 10 Executive moves:
Jeff Moriarty, SVP Product Management at About, Inc.
ex-New York Times
Larry Blackledge, CEO at Active-Semi, Inc.
ex-TI
Howard Doherty, VP Sales at Arkeia Software
x Symphoniq, NetContinuum
Michael Wolfe, EIR at Benchmark Capital
ex-Symantec, Vontu
Mark Swoboda, CEO at Bridgelux, Inc.
re-added
Niraj Katwala, CTO at Healthline Networks, Inc.
Promotion- Was VP Engineering, now CTO
Jim Allison, SVP Engineering at Livescribe, Inc.
ex-Xumii, iVAST, Palm
Jerry Skurla, VP Marketing at NitroSecurity
ex-Bradford Networks, Nortel Networks, Bay Networks, Wellfleet
Matt Weil, VP Sales at Teneros, Inc.
ex-Neustar, UltraDNS
Om Malik, Partner at True Ventures
ex-Forbes.com
Since our last post, there have been 70 executive moves at the companies we track, 32 Executives where added at 23 companies and 38 Executives where removed from 25 companies. For the full version of our weekly executive moves archive, please visit www.technames.com or call (925)831-2900.
The Technames Pulse has been created purely for entertainment. We make no recommendations or endorsements of any kind and comments made within the Pulse should not be considered recommendations or endorsements.